Vanessa Bolejack

17.0k total citations · 1 hit paper
16 papers, 1.5k citations indexed

About

Vanessa Bolejack is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Vanessa Bolejack has authored 16 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 10 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Vanessa Bolejack's work include Multiple Myeloma Research and Treatments (10 papers), Cancer Treatment and Pharmacology (7 papers) and Lung Cancer Treatments and Mutations (5 papers). Vanessa Bolejack is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Cancer Treatment and Pharmacology (7 papers) and Lung Cancer Treatments and Mutations (5 papers). Vanessa Bolejack collaborates with scholars based in United States, United Kingdom and Spain. Vanessa Bolejack's co-authors include Peter Goldstraw, John Crowley, Ramón Rami–Porta, John J. Crowley, Leslie H. Sobin, Mark Krasnik, Patti A. Groome, Catherine Kennedy, Kenji Suzuki and Charles F. Thomas and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Vanessa Bolejack

15 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

2015 530 citations Ramón Rami–Porta, Vanessa Bolejack et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vanessa Bolejack United States	11	1.1k	600	340	270	175	16	1.5k
Giuseppe Fornarini Italy	22	562 0.5×	597 1.0×	178 0.5×	245 0.9×	165 0.9×	125	1.3k
C. Sternberg Italy	16	606 0.6×	397 0.7×	143 0.4×	210 0.8×	159 0.9×	67	1.1k
J. Garcia‐Vargas United States	13	405 0.4×	495 0.8×	249 0.7×	503 1.9×	169 1.0×	62	1.2k
Antoine Yver United States	17	420 0.4×	1.3k 2.1×	428 1.3×	344 1.3×	386 2.2×	36	1.8k
Youling Gong China	21	662 0.6×	534 0.9×	240 0.7×	439 1.6×	47 0.3×	89	1.4k
Marie‐Cécile Bozonnat France	7	1.6k 1.4×	710 1.2×	414 1.2×	80 0.3×	52 0.3×	12	1.9k
C. Calandri Italy	15	920 0.8×	944 1.6×	64 0.2×	387 1.4×	165 0.9×	24	1.5k
Pasquale Rescigno Italy	22	773 0.7×	317 0.5×	229 0.7×	381 1.4×	73 0.4×	82	1.3k
Josiane Otto France	20	906 0.8×	1.1k 1.8×	204 0.6×	228 0.8×	40 0.2×	59	1.6k
Ulrika Harmenberg Sweden	23	1.0k 0.9×	736 1.2×	281 0.8×	693 2.6×	75 0.4×	57	1.7k

Countries citing papers authored by Vanessa Bolejack

Since Specialization

Citations

This map shows the geographic impact of Vanessa Bolejack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanessa Bolejack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanessa Bolejack more than expected).

Fields of papers citing papers by Vanessa Bolejack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanessa Bolejack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanessa Bolejack. The network helps show where Vanessa Bolejack may publish in the future.

Co-authorship network of co-authors of Vanessa Bolejack

This figure shows the co-authorship network connecting the top 25 collaborators of Vanessa Bolejack. A scholar is included among the top collaborators of Vanessa Bolejack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanessa Bolejack. Vanessa Bolejack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Rami–Porta, Ramón, Vanessa Bolejack, John Crowley, et al.. (2015). The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology. 10(7). 990–1003. 530 indexed citations breakdown →

Rami–Porta, Ramón, Vanessa Bolejack, Dorothy J. Giroux, et al.. (2014). The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology. 9(11). 1618–1624. 252 indexed citations

Foss, Francine M., Nelida Sjak-Shie, André Goy, et al.. (2013). A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leukemia & lymphoma. 54(7). 1373–1379. 47 indexed citations

Rami–Porta, Ramón, Vanessa Bolejack, & Peter Goldstraw. (2011). The New Tumor, Node, and Metastasis Staging System. Seminars in Respiratory and Critical Care Medicine. 32(1). 44–51. 36 indexed citations

Barlogie, Bart, Vanessa Bolejack, Michael J. Schell, & John Crowley. (2010). Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Annals of Hematology. 90(4). 423–428. 25 indexed citations

Crowley, John, John D. Shaughnessy, Vanessa Bolejack, et al.. (2010). Cure fractions (CF) modeled from event-free survival and complete response duration plots in total therapy (TT) trials for newly diagnosed multiple myeloma (MM).. Journal of Clinical Oncology. 28(15_suppl). 8119–8119. 1 indexed citations

Ludwig, H., et al.. (2009). A222 Survival and Years of Life Lost in Different Age Categories of Patients with Multiple Myeloma. Clinical Lymphoma & Myeloma. 9. S37–S37.

Hussein, Mohamad A., Vanessa Bolejack, Jeffrey A. Zonder, et al.. (2009). Phase II Study of Thalidomide Plus Dexamethasone Induction Followed by Tandem Melphalan-Based Autotransplantation and Thalidomide-Plus-Prednisone Maintenance for Untreated Multiple Myeloma: A Southwest Oncology Group Trial (S0204). Journal of Clinical Oncology. 27(21). 3510–3517. 19 indexed citations

Barlogie, Bart, John D. Shaughnessy, Elias Anaissie, et al.. (2009). Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.. Blood. 114(22). 744–744. 2 indexed citations

10.

Zonder, Jeff, John J. Crowley, Vanessa Bolejack, et al.. (2008). A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results. Journal of Clinical Oncology. 26(15_suppl). 8521–8521. 14 indexed citations

11.

Groome, Patti A., Vanessa Bolejack, John J. Crowley, et al.. (2007). The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. Journal of Thoracic Oncology. 2(8). 694–705. 468 indexed citations

12.

Zonder, Jeffrey A., John Crowley, Mohamad A. Hussein, et al.. (2007). Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232.. Blood. 110(11). 77–77. 58 indexed citations

13.

Pineda‐Roman, Mauricio, Vanessa Bolejack, Elias Anaissie, et al.. (2006). Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. British Journal of Haematology. 136(3). 393–399. 51 indexed citations

14.

Govindan, Ramaswamy, John Crowley, Lee S. Schwartzberg, et al.. (2006). Phase II Trial of Bexarotene Capsules in Patients With Advanced Non–Small-Cell Lung Cancer After Failure of Two or More Previous Therapies. Journal of Clinical Oncology. 24(30). 4848–4854. 24 indexed citations

15.

Barlogie, Bart, E. Anaissie, Vanessa Bolejack, et al.. (2006). High CR and near-CR rate with bortezomib incorporated into up-front therapy of multiple myeloma with tandem transplants. Journal of Clinical Oncology. 24(18_suppl). 7519–7519. 5 indexed citations

16.

Hussein, Mohamad A., Andrzej Jakubowiak, Vanessa Bolejack, et al.. (2006). S0204: Melphalan (MEL)-Based Tandem Autotransplants (TAT) for Multiple Myeloma (MM) with Thalidomide/Dexamethasone (TD) Induction and Thalidomide/Prednisone (TP) Maintenance: A Phase II Trial of the Southwest Oncology Group.. Blood. 108(11). 3088–3088. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact